
1 2

3

1 -



1

2

1 2

1 2

CLAIMS

- Sub β_1 1. A method for inhibiting the action of TNF- α for treating nerve disorders in a subject by administering a TNF- α inhibitor comprising administering to said subject a therapeutically effective dosage of said TNF- α inhibitor wherein said TNF- α inhibitor is CDP-571 (HUMICADE^m), D2E7, or CDP-870.
 - 2. The method of claim 1, wherein the subject is a vertebrate.
 - 3. The method of claim 2, wherein the vertebrate is a mammal.
 - 4. The method of claim 3, wherein the mammal is a human.
- 5. The method of claim 1, wherein said nerve disorder is a spinal disorder.
- 6. The method of claim 1, wherein said nerve disorder is nerve root injury.
- 7. The method of claim 1, wherein said nerve disorder is caused by herniated discs.
 - 8. The method of claim 1, wherein said nerve disorder is sciatica.
- 9. The method of claim 1, wherein said nerve disorder involves pain.
- 10. The method of claim 1, wherein said nerve disorder is nucleus pulposus-induced nerve injury.

1	11. The method of claim 1, wherein said nerve disorder is spinal		
2	cord compression.		
1	12. The method of claim 1, wherein said TNF- α inhibitor is		
2	administered systemically or locally.		
1	13. The method of claim 1, wherein said TNF- α inhibitor is		
2	administered parenterally.		
	14. The method of claim 1, wherein said TNF- α inhibitor is		
	administered intramuscularly, intravenously, subcutaneously, orally, or rectally.		
· 有 . A	15. The method of claim 14, wherein said TNF- α inhibitor is		
ਵੇਲਾਂ 1 2 =	administered intravenously by injection or infusion.		
.			
	16. The method of claim 15, wherein said TNF-α inhibitor is		
12 O	administered orally at a dosage of about 20 mg to about 1,500 mg.		
1	17. The method of claim 1, wherein the TNF-α is D2E7 and is		
2	administered in a dosage of about 0.1 mg/kg to about 50 mg/kg body weight of said		
3	subject.		
1	50 h2 18. The method of claim 1, wherein the TNF-α is CDP-870 and is		
2	administered in a dosage of about 1 mg/kg to about 50 mg/kg body weight of said		
3	subject.		
1	19. A method for inhibiting the action of TNF-α for treating nerve		
2	disorders in a subject by administering a TNF-α inhibitor comprising administering		
3	to said subject a therapeutically effective dosage of said TNF-α inhibitor wherein		
4	said TNF-α inhibitor is a lactoferrin, CT3, ITF-2357, PD-168787, CLX-1100, M-		

2

1

2

3

4

5

6

1

PGA, NCS-700; PMS-601, RDP-58, TNF-484A, PCM-4, CBP-1011, SR-31747, AGT-1, Solimastat, CPI-3697, NR58-3.14.3, RIP-3, Sch-23863, or SH-636.

Suo β3 20. A pharmaceutical composition for treating nerve disorders in a subject comprising a therapeutically effective amount of a TNF-α inhibitor wherein said TNF-α inhibitor is CPP-571 (HUMICADETM), D2E7, or CDP-870, and a pharmaceutically acceptable carrier, and wherein said pharmaceutical composition inhibits nerve injury when administered to said subject.

- 21. The pharmaceutical composition of claim 20, wherein the subject is a vertebrate.
- 22. The pharmaceutical composition of claim 21, wherein the vertebrate is a mammal.
- 23. The pharmaceutical composition of claim 20, wherein the mammal is a human.
- 24. The pharmaceurical composition of claim 20, wherein said monoclonal antibody is D2E7 in a dosage amount of about 0.1 mg/kg to about 50 mg/kg body weight of said subject.
- The pharmaceutical composition of claim 20, wherein said monoclonal antibody CDP-870 in an amount of about 1.0 mg/kg to about 50 mg/kg body weight of said subject.
- 26. The pharmaceutical composition of claim 20, wherein said nerve disorder is selected from the group consisting of a spinal disorder, a nerve root injury, a nerve disorder caused by herniated discs, a nerve disorder involving pain, a nucleus pulposus-induced nerve injury, a spinal cord compression, and

5

1

2

3

SCI	at	ıc	a.

- 27. The pharmaceutical composition of claim 20, wherein said pharmaceutical composition is formulated for intravenous, intramuscular, oral, rectal, or subcutaneous administration.
- 28. The pharmaceutical composition of claim 20, wherein said pharmaceutical composition is formulated for parenteral administration.
- 29. A pharmaceutical composition for treating nerve disorders in a subject comprising a therapeutically effective amount of a TNF-α inhibitor wherein said TNF-α inhibitor is a lactofertin, CT3, ITF-2357, PD-168787, CLX-1100, M-PGA, NCS-700; PMS-601, RDP-68, TNF-484A, PCM-4, CBP-1011, SR-31747, AGT-1, Solimastat, CH-3697, NR38-3.14.3, RIP-3, Sch-23863, or SH-636, and a pharmaceutically acceptable carrier, and wherein said pharmaceutical composition inhibits nerve injury when administered to said subject.

